Bioengineering of Neonatal Porcine Islets to Delay Immune-Mediated Rejection

  • T1D affects around 20 million individuals worldwide and over 1.6 million in the US.
  • Pancreatic islet transplantation can treat Type 1 diabetes, but transplanted islets are susceptible to immune-mediated destruction.
  • The inventors propose to address this problem by encapsulating the islets with a protective biomaterial and cotransplanting them with drug-eluting micelles

Website

https://uab.flintbox.com/technologies/C0F2D43C3D6B4025906367B714DA392E

Advantages

Type 1 diabetes (T1D) is an autoimmune disease resulting in pancreatic beta-cell destruction. Beta cells are a type of cell found in pancreatic islets that synthesize and secrete insulin and amylin. T1D affects around 20 million individuals worldwide and over 1.6 million in the US. T1D can be treated by transplantation of pancreatic islets, but transplanted islets are susceptible to immune-mediated destruction. The inventors propose to address this problem by encapsulating the islets with a protective biomaterial to protect against recognition by the immune system and cotransplanting them with drug-eluting micelles. Islet encapsulation and the use of drug-eluting micelles may provide immunoprotection to preserve islet function and prevent immune responses against the islet graft following transplantation. The global Type-1 Diabetes Treatment market size is projected to reach US$ 7034.4 million by 2027, from US$ 5020 million in 2020, at a CAGR of 4.5% during 2021-2027.

Potential Applications

  • T1D treatment
  • Drug delivery
  • Immunomodulation
  • Organ Transplantation
  • Endocrine diseases

Website

https://uab.flintbox.com/technologies/C0F2D43C3D6B4025906367B714DA392E

Advantages

Type 1 diabetes (T1D) is an autoimmune disease resulting in pancreatic beta-cell destruction. Beta cells are a type of cell found in pancreatic islets that synthesize and secrete insulin and amylin. T1D affects around 20 million individuals worldwide and over 1.6 million in the US. T1D can be treated by transplantation of pancreatic islets, but transplanted islets are susceptible to immune-mediated destruction. The inventors propose to address this problem by encapsulating the islets with a protective biomaterial to protect against recognition by the immune system and cotransplanting them with drug-eluting micelles. Islet encapsulation and the use of drug-eluting micelles may provide immunoprotection to preserve islet function and prevent immune responses against the islet graft following transplantation. The global Type-1 Diabetes Treatment market size is projected to reach US$ 7034.4 million by 2027, from US$ 5020 million in 2020, at a CAGR of 4.5% during 2021-2027.

Potential Applications

  • T1D treatment
  • Drug delivery
  • Immunomodulation
  • Organ Transplantation
  • Endocrine diseases

Contact Information

Name: Francis T Crittenden

Email: ftgcritt@uab.edu

Phone: (205) 975-6851